A5014362214- Estrogen and related hormone effects
- interferon and immune responses
- Ubiquitin and proteasome pathways
- Acute Myeloid Leukemia Research
- Cancer therapeutics and mechanisms
- Histiocytic Disorders and Treatments
- Immune cells in cancer
- Hematopoietic Stem Cell Transplantation
- Nuclear Structure and Function
- Computational Drug Discovery Methods
- Cell death mechanisms and regulation
- RNA regulation and disease
- Inflammasome and immune disorders
- NF-κB Signaling Pathways
- Hemoglobinopathies and Related Disorders
- HER2/EGFR in Cancer Research
- Surgical Simulation and Training
- Toxoplasma gondii Research Studies
- Advanced Breast Cancer Therapies
- Cardiac, Anesthesia and Surgical Outcomes
- Diversity and Career in Medicine
Loyola University Chicago
2024-2025
Loyola University Medical Center
2022-2024
OBJECTIVE Prematch research productivity is a heavily utilized metric in evaluating neurosurgery residency applicants. With the rise output by successfully matched candidates and so-called publication arms race, there growing interest understanding quality impact of conducted medical students who secure positions. This study aimed to characterize into 2023, identify predictors productivity, explore implications on match outcomes. METHODS First-year residents from 2023 were identified via...
Abstract Myelodysplastic syndromes (MDS) are a heterogeneous group of pre-leukemic hematopoietic disorders characterized by cytopenia in peripheral blood due to ineffective hematopoiesis and normo- or hypercellularity morphologic dysplasia bone marrow (BM). An inflammatory BM microenvironment programmed cell death stem/progenitor cells (HSPCs) thought be the major causes MDS. Pyroptosis, apoptosis necroptosis (collectively, PANoptosis) observed tissues MDS patients, suggesting an important...
Resistance to endocrine therapies remains a major clinical hurdle in breast cancer. Mutations estrogen receptor alpha (ERα) arise after continued therapeutic pressure. Next generation selective modulators and degraders/downregulators (SERMs SERDs) show efficacy, but responses are often non-durable. A tyrosine serine point mutation at position 537 the ERα ligand binding domain (LBD) is among most common pathogenic alteration this setting. It enables therapy resistance by superceding intrinsic...
Lymphoid-primed multipotent progenitor (LMPP)-like and granulocyte-monocyte (GMP)-like leukemia stem cells (LSCs) co-exist in the blood of most patients with acute myeloid (AML). Complete elimination both types LSCs is required to cure AML. Using an MLL-AF9-induced murine AML model, we studied role hematopoietic cytokines survival LMPP- GMP-like LSCs. We found that SCF or FLT3L promotes LMPP-like by stimulating Stat5-mediated Mcl1 expression, whereas interleukin-3 (IL-3) IL-6 induces...
Resistance to endocrine therapies remains a major clinical hurdle in breast cancer. Mutations estrogen receptor alpha (ERα) arise after continued therapeutic pressure. Next generation selective modulators and degraders/downregulators (SERMs SERDs) show efficacy, but responses are often non-durable. A tyrosine serine point mutation at position 537 the ERα ligand binding domain (LBD) is among most common pathogenic alteration this setting. It enables therapy resistance by superceding intrinsic...
<title>Abstract</title> Resistance to endocrine therapies remains a major clinical hurdle in breast cancer. Mutations estrogen receptor alpha (ERα) arise after continued therapeutic pressure. Next generation selective modulators and degraders/downregulators (SERMs SERDs) show efficacy, but responses are often non-durable. A tyrosine serine point mutation at position 537 the ERα ligand binding domain (LBD) is among most common pathogenic alteration this setting. It enables therapy resistance...